RBC Capital raised the firm’s price target on Becton Dickinson (BDX) to $210 from $202 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC believes it is positioned to grow mid-single-digits due to its strong durable core with high recurring revenue.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson announces expansion of BD MAX System menu
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Unusually active option classes on open December 4th
- Becton Dickinson, ChemoGLO announce strategic collaboration
- Becton Dickinson price target raised to $210 from $197 at Morgan Stanley